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Background: Analyses of the efficacy and safety of transcatheter aortic valve replacement (TAVR) in most coun-
tries have been based on outcomes obtained in accordance with national practice guidelines and monitoring 
protocols. The purpose of this study is to share our experience regarding the process for establishing guidelines 
and monitoring protocols for the use of TAVR in Korea, in the hopes that it may be helpful to others under-
going a similar process in their own country. Methods: The Korean guidelines for TAVR were established on June 
1, 2015 in through a tri-party agreement involving the Department of Health and Welfare, the Korean Society of 
Thoracic and Cardiovascular Surgery and the Korean Society of Cardiology. We agreed to monitor the guidelines 
transparently and to exchange opinions regarding amendments or continuation of its contents after 3 years of 
monitoring. Results: The monitoring meetings were not held as regularly as agreed, and monitoring was also 
made difficult by insufficient and incomplete data. Nevertheless, during the meetings, measures to improve the 
monitoring process were discussed, and accordingly, an agreement was made to continue the monitoring process, 
with the aim of completing data collection by 2018. Conclusion: Compliance with guidelines is critical for assess-
ing the efficacy and safety of TAVR. Moreover, the TAVR monitoring process must be properly conducted for an 
accurate evaluation to be made. Any country planning to introduce TAVR may encounter difficulties with regards 
to the optimal initiation strategy and subsequent monitoring. Nevertheless, continued efforts should be made to 
persuade the government and the corresponding medical societies to facilitate the optimal application of TAVR.
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Introduction
Aortic stenosis is becoming an increasingly com-
mon valvular heart disease in the elderly. Recently, 
transcatheter aortic valve replacement (TAVR) has 
emerged as a viable treatment option for patients 
with high-risk or inoperable severe aortic stenosis. 
The volume of TAVR has dramatically increased since 
its seminal case presented by Cribier et al. [1] in 
2002. The success of this case led to more and more 
surgical aortic valve replacements (SAVR) being re-
placed by TAVR as the primary therapy of choice.
Despite the increasing importance of TAVR, many 
Western countries with high-volume TAVR practices 
have come to recognize certain limitations of TAVR 
in comparison with surgical treatment as experience 
has accumulated. Consequently, many countries have 
established their own practice guidelines and mon-
itoring protocols for the safe and effective application 
of TAVR. For this purpose, a multidisciplinary team 
approach seems to be the best method for identify-
ing ideal candidates and devising intraoperative and 
postoperative management strategies. Serial pub-
lications regarding the outcomes of TAVR have at-
tributed significant improvements over time to not 
only an increasing depth of experience, but also to 
the evolution of newer-generation devices aimed at 
addressing the limitations of earlier devices.
The Korean Society of Thoracic and Cardiovascular 
Surgery (KTCVS) has continually stressed the neces-
sity of developing adequate guidelines and monitor-
ing protocols for these purposes since the first TAVR 
procedure was performed in Korea in 2010. The 
Korean guidelines for TAVR were established in June 
2015 through a tri-party agreement that included the 
Korean government and the Korean Society of 
Cardiology, as well as the KTCVS. Currently, data col-
lection for monitoring the outcomes of TAVR in 
Korea is an ongoing process. Through this study, we 
aim to share our experiences in establishing the 
TAVR guidelines and monitoring protocols.
The enactment process of the Korean 
guidelines for transcatheter aortic 
valve replacement
After the first TAVR procedure was performed in 
Korea in 2010, it was primarily performed in several 
select hospitals without medical insurance coverage. 
Meanwhile, the Korean government and the Korean 
Medical Association came to recognize TAVR as a po-
tentially effective and useful procedure for treating 
patients with high-risk or inoperable severe sympto-
matic aortic stenosis. However, data were lacking to 
compare the intermediate- to long-term outcomes of 
TAVR to those of SAVR with regard to cost-effective-
ness, safety, and efficacy. In August 2013, the medical 
practice assessment committee of the Korean govern-
ment concluded that further evaluation of TAVR was 
needed in this regard. The TAVR advisory committee, 
composed of members from the KTCVS, the Korean 
Society of Cardiology, and the Korean government, 
was organized in 2014 to address this very issue. 
The development of Korean guidelines for TAVR was 
initiated in April 2014. Discussions were held with 
the specific aim of establishing the indications, con-
traindications, and standards for the implementation 
of TAVR and related evaluation methods. We made 
efforts to follow the original guidelines for TAVR es-
tablished by the United States [2], European Union 
[3], and Japan [4]. However, subsequent negotiations 
were needed to develop our own guidelines adapted 
to our medical situation. In addition, medical ex-
penditures related to TAVR were supposed to be re-
imbursed following Korean guidelines, and a corre-
sponding administrative decree was enacted. 
Previously, a tri-party agreement was arrived at for a 
similar model, involving a heart team approach, for 
the treatment of coronary artery disease in Korea. 
However, in reality, there were limitations regarding 
the degree to which the ideal role of the heart team 
was fulfilled for this disease entity. Based on pre-
vious experiences, negotiations resulting in a tri-party 
agreement were conducted to develop the Korean 
guidelines for TAVR, with the goal of improving its 
implementation. After a total of 3 TAVR advisory 
committee meetings, held from May 20, 2014 to 
October 27, 2014, all members were satisfied that 
the newly enacted Korean guidelines for TAVR ad-
equately reflected our national circumstances. In ad-
dition, further clauses to reinforce standards for 
qualified manpower, facilities, and equipment were 
added. The Korean guidelines, including stipulations 
for further monitoring, were finalized on December 
27, 2014, after all members of the advisory commit-
tee agreed to the content.
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Table 1. Follow-up monitoring data of TAVR (June 1, 2015 to 
November 30, 2015)
Variable No. of patients (%)
Heart team approach
Total 64 (100.0)
All participants 46 (71.9)
Some participants 18 (28.1)
Cardiologist: 2 cardiologists 64 (100.0)
Cardiac surgeon
2 Participants 62 (96.9)
1 Participants 2 (3.1)
Anesthesiologist
Participation 60 (93.7)
No participation 4 (6.3)
Radiologist
Participation 46 (71.9)
No participation 18 (28.1)
Reason for deciding to perform TAVR
Total 64 (100.0)
Following indications 14 (21.9)
Consideration of risk due to old age 
and comorbidities
33 (51.6)
Patient’s wish 13 (20.3)
No reason 4 (6.2)
Standby staff (cardiac surgeon, perfusionist)
Total 64 (100.0)
Standby 20 (31.3)
No standby 44 (68.7)
TAVR, transcatheter aortic valve replacement.
The major difference between the Korean TAVR 
guidelines and those of other nations (e.g., the United 
States and Japan) is that all aspects of our regu-
lations regarding indications, contraindications, and 
standards for TAVR application were loosened to 
provide greater opportunities for hospitals wishing to 
perform TAVR. The committee ultimately agreed that 
all TAVR procedures should be performed by a heart 
team during the mandatory 3-year monitoring period, 
after which further revisions could be made to the 
guidelines as needed. During this period, the govern-
ment decided on a policy of 20% reimbursement for 
medical expenditures related to TAVR by the national 
medical insurance program, which was the first mod-
el of conditional coverage in Korea. Any future 
amendments modifying the reimbursement pro-
portion would only become possible after June 2018, 
following the final analysis of the 3-year TAVR mon-
itoring period. Based on these provisions, the Korean 
guidelines for TAVR were established by an admin-
istrative decree on June 1, 2015 (Appendices 1, 2).
The course of transcatheter aortic valve 
replacement monitoring since the 
establishment of the Korean guidelines
A preliminary meeting for monitoring activities 
was held under the auspices of the Health Insurance 
Review and Assessment Service (HIRA; March 30, 
2015) prior to the launch of the advisory committee 
for establishing the Korean guidelines for TAVR and 
the monitoring protocol. The monitoring advisory 
committee members consisted of 2 reviewers from 
the HIRA, 2 members of the medical practice assess-
ment committee, 3 members each of the KTCVS and 
the Society of Cardiology, and a statistical advisor. 
The statistical advisor was included in the monitor-
ing advisory committee for assistance with analyzing 
the results of the upcoming 3-year monitoring period 
(June 2015 to May 2018). It was agreed that the par-
ticipating hospitals should monitor outcomes at 
5-time points after TAVR (before discharge, 30 days 
to 6 months, 1 year, 2 years, and 3 years) and sub-
mit their results for scrutiny by the advisory 
committee. The first monitoring meeting took place 
with the HIRA 6 months after the Korean guidelines 
were implemented (December 14, 2015). Upon re-
view of the monitoring results during the previous 6 
months (June 1, 2015 to November 30, 2015), the 
committee found that the data were insufficient and 
that no reasons were provided for not strictly abid-
ing by the set indications for TAVR (Table 1). The 
committee decided to collect further revised monitor-
ing data within the next 3 months from the partic-
ipating hospitals, and held a follow-up meeting. The 
administrative decree for TAVR was modified accord-
ingly on February 2, 2016, after the first meeting 
(Appendix 2).
The second monitoring meeting was not held as 
scheduled, although the KTCVS made several requests 
through February 2017 that the HIRA hold the 
meeting. It was not until March 2, 2017 that the sec-
ond monitoring meeting was held (Table 2). 
However, the meeting was not productive, as the 
monitoring data submitted by the HIRA for review 
were generally incomplete. After this meeting, it was 
agreed that further monitoring meetings should be 
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Table 2. Follow-up monitoring data of TAVR (December 1, 2015 
to June 30, 2016)
Variable
No. of 
patients (%)
Heart team approach
Total 153 (100.0)
All participants 145 (94.8)
Some participants 8 (5.2)
Cardiologist: 2 cardiologists 153 (100.0)
Cardiac surgeon
2 Participants 147 (96.1)
1 Participants 6 (3.9)
Anesthesiologist: participation 153 (100.0)
Radiologist
Participation 151 (98.7)
No participation 2 (1.3)
Reason for deciding to perform TAVR
Total 153 (100.0)
Following indications 53 (35.3)
Consideration of risk due to old age and 
comorbidities
80 (51.7)
Patient’s wish 12 (7.8)
No reason 8 (5.2)
Standby staff (cardiac surgeon, perfusionist)
Total 153 (100.0)
Standby 93 (60.8)
No standby 50 (32.7)
No answer 10 (6.5)
Standby of heart-lung machine or extracorporeal 
membrane oxygenation
Total 153 (100.0)
Yes 91 (59.5)
No 62 (40.5)
TAVR, transcatheter aortic valve replacement.
routinely held at least every 6 months, with HIRA 
submitting complete monitoring data with all rele-
vant information for proper evaluation.
The last monitoring meeting was held on July 4, 
2017, at which time all advisory committee members 
agreed to stricter enforcement of the TAVR guide-
lines, revisions of some clauses to improve the guide-
lines, and clearer representation to avoid misinter-
pretation or confusion. The committee also agreed to 
ensure that the statistical data analysis would be ob-
jective through outsourcing to a third party; on this 
basis, the cost-effectiveness of TAVR, its outcomes, 
and medical reimbursement will be discussed in 
2018 after 3 years of monitoring.
Discussion
TAVR is a relatively new and evolving technology 
for treating patients with high-risk or inoperable se-
vere symptomatic aortic stenosis. Since the in-
dications for TAVR have been updated to include in-
termediate-risk patients as a class IIa indication in 
the most recent American College of Cardiology 
(ACC)/American Heart Association TAVR guidelines 
[5], it has become increasingly likely that TAVR will 
be applied to even lower-risk patients in the real 
world, without the scrutiny of objective clinical trials. 
TAVR has already been performed in over 100,000 
cases worldwide, and in the United States alone, 
which is one of the leading nations performing TAVR, 
over 50,000 TAVR procedures have been conducted 
since Food and Drug Administration approval in 
2011 [6].
Many clinical trials, including the PARTNER (Place-
ment of Aortic Transcatheter Valve) and SURTAVI 
(Surgical Replacement and Transcatheter Aortic Valve 
Implantation) trials that are underway, have pub-
lished comparative TAVR outcomes for a variety of 
endpoints, including survival, associated complica-
tions, cost-effectiveness, and quality of life. However, 
the objective evaluation of each step of TAVR im-
plementation is complex, as the usual TAVR candi-
dates are high-risk patients with multiple comorbidities. 
Furthermore, the evaluation of TAVR must account 
for several issues, including standards regarding the 
facility where the procedure is performed, the pre-
operative evaluation for deciding upon suitability for 
TAVR, the experience of the surgeon, and the ad-
equacy of training, not only for conducting the actual 
procedure, but also (perhaps more importantly) to 
effectively deal with difficult complications and post-
operative care. Therefore, for the overall success of 
TAVR, it is essential for the heart team to function 
properly; this involves obligatory cooperation be-
tween the cardiac surgeon and the cardiologist. 
Historically, TAVR was launched in 2010 in Korea by 
several hospitals, without the benefit of government 
reimbursement by the national health insurance 
system. However, the Department of Health and 
Welfare and the relevant professional medical soci-
eties have recognized TAVR as a new technology that 
should, in principle, be managed through a multi-
disciplinary heart team approach. With this general 
Transcatheter Aortic Valve Replacement
− 235 −
consensus, the advisory committee for establishing 
TAVR guidelines in Korea was formed. The KTCVS 
led efforts to revise, rather than to simply adopt, the 
existing published guidelines from other nations in 
order to accommodate the differences in the medical 
systems and conditions under which TAVR may be 
performed in Korea. Therefore, to design and estab-
lish our own TAVR guidelines that would be opti-
mally suited to the Korean medical environment, the 
current TAVR guidelines and standards of use were 
modified, using those in the United States [2], 
European Union [3], and Japan [4] as references.
The original TAVR guidelines were revised during 
3 TAVR advisory committee meetings with regard to 
the indications, contraindications, and all standards 
for human resources, facility, and equipment appro-
priate to the Korean medical environment. As the 
role of the heart team approach was fully recognized 
as essential for successful TAVR, the importance of 
using a heart team approach for TAVR was specified 
in the Korean guidelines (Appendix 1).
The detailed standards of TAVR implementation in 
Japan and the United States are as follows:
1) Qualifications to begin a TAVR program in the 
United States [2]
(1) ≥50 total aortic valve replacements (AVRs) in 
the previous year prior to TAVR, including ≥10 
high-risk patients
(2) ≥2 physicians with cardiac surgery privileges
(3) ≥1,000 catheterizations per year, including ≥400 
percutaneous coronary interventions (PCIs) per year
2) Qualifications to begin a TAVR program in 
Japan [4]
(1) ≥20 AVRs per year
(2) ≥3 Cardiac surgeons
(3) ≥100 PCIs per year
(4) ≥10 Aortic stent grafts per year
(5) ≥200 Instances of transesophageal echocardio-
graphy
However, in contrast to these strict conditions, the 
prerequisite criteria for the institutional initiation 
and continuation of a TAVR program in Korea are 
considerably laxer (Appendix 1).
In terms of the role of heart team, the Korean 
guidelines, approved by all members of the advisory 
committee, also eased the regulatory requirements 
for institutional TAVR application to include even 
cases that would otherwise be deemed controversial 
and possibly contraindicated for TAVR according to 
published international guidelines. However, as a 
safeguard, the administrative decree on the practice 
of TAVR in Korea specified that the heart team in 
each hospital should faithfully submit any and all 
reasons for not strictly abiding by the set indications 
for TAVR for monitoring purposes.
At the outset, it was agreed that only 20% of the 
medical expenditures relating to the device fee would 
be reimbursed by the national medical insurance sys-
tem starting in June 2015. It was also decided that 
any amendments to this proportion would only be 
made after the final assessment of the mandatory 
monitoring outcomes in 2018. Thus far, despite suc-
cinct publication of the official guidelines and the ad-
ministrative decree for TAVR, several factors have 
hindered the monitoring process. TAVR monitoring 
meetings were held only twice during the past 2 
years (from June 2015 to May 2017). This was fur-
ther compounded by poor data preparation, which 
significantly hindered any meaningful discussions 
during the monitoring meetings (Tables 1, 2).
With an international platform provided by the an-
nual meeting of the Asian Society of Cardiovascular 
and Thoracic Surgery in late March 2017, the KTCVS 
was able to share the current status of TAVR in 
Korea and to hold discussions with international col-
leagues on overcoming obstacles relating to establish-
ing nationwide TAVR practices. During this meeting, 
discussions were also held with Asian and Western 
colleagues on the role of cardiac surgeons in the 
heart team. The discussions showed that in most na-
tions with well-established nationwide TAVR pro-
grams, TAVR was implemented by following clearly 
defined protocols accompanied by an accurate analy-
sis of monitoring data on outcomes. We also dis-
cussed ways to overcome the difficulties relating to 
TAVR monitoring with government officials and par-
liamentary members. We informed them of the im-
portance of monitoring TAVR procedures, and pre-
sented arguments supporting the importance of accu-
rate monitoring for ensuring the safety and efficacy 
of TAVR implementation. Thus, the meeting held on 
July 4, 2017 was concluded by all members of the 
advisory committee agreeing to concentrate future ef-
forts to ensure complete and faithful data collection 
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and objective statistical data analysis through out-
sourcing to a third party, as well as to hold regular 
TAVR monitoring meetings.
In 2017, the ACC suggested an expert consensus 
decision pathway for TAVR in the management of 
aortic stenosis [7]. They stated that patient manage-
ment relies on a shared decision-making approach 
based on a comprehensive understanding of the 
risk-benefit ratio of different treatment strategies and 
integration of patient preferences and values. In ad-
dition, the heart valve team should emphasize that 
the purpose of valvular intervention is to improve 
symptoms and/or to prolong survival, while minimiz-
ing adverse outcomes associated with the inter-
vention [8]. We cannot avoid all the possible compli-
cations of TAVR, despite a strongly collaborative 
heart team, as urgently occurring adverse events are 
not completely predictable or preventable. Neverthe-
less, data collection as part of an accurate monitoring 
process will provide valuable information that will 
minimize the risk of such complications and ulti-
mately make the implementation of TAVR safer and 
more effective.
Finally, quality assessment of the entire spectrum 
of the medical landscape is of paramount import, and 
TAVR quality metrics are important for assessing the 
appropriateness of TAVR in an objective and widely 
applicable manner. The 2 fundamental components 
determining the quality of health care at TAVR cen-
ters of excellence are the use of a heart team and 
the active participation and management of a registry 
program [8]. Maintaining a well-run registry is essen-
tial for tracking and monitoring adverse events, pre-
vents missed follow-up evaluations, and allows in-
stitutions to implement necessary measures or treat-
ment in a timely manner, thereby preventing the oc-
currence of more serious adverse events. Objective 
analysis and retrospective reflection upon past practi-
ces allow revisions of current limitations to be im-
plemented where necessary and lead to optimal step-
wise improvements in patient care based on past 
experiences. Patient safety should be the top priority 
in any TAVR program, above all other considerations. 
To ensure the optimal implementation of the system, 
the will of the government is also important. To this 
end, maintaining a program of prospective monitor-
ing is of paramount importance.
Conclusion
Compliance with TAVR guidelines is essential for 
ensuring efficacy and safety in treating high-risk or 
inoperable patients with severe aortic stenosis. 
Moreover, the TAVR monitoring process should be 
appropriately conducted to ensure accurate evalua-
tion of all aspects of activities relating to TAVR, as 
well as the directly related outcomes. Although each 
country has unique circumstances, those planning to 
initiate TAVR will inevitably encounter various diffi-
culties relating to the initiation and subsequent mon-
itoring of TAVR. However, continued efforts should 
be made to persuade members of the relevant gov-
ernmental institutions and professional societies to 
take steps promoting the seamless application of 
TAVR.
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